Skip to main content
AUPH logo

AUPH · Aurinia Pharmaceuticals Inc.

Track AUPH — free
$14.70 -0.19 (-1.28%) At close · Nov 20
Market Cap
$1.97B
Shares
134.00M
Volume · Nov 20 1.34M Avg daily vol (3M) 864.89K

Price & Indicators

 

Key stats

Close
$14.70
Fri 20 Nov
Open
$14.69
Fri 20 Nov
Average volume, 30 days
923K
shares a session
Short interest
7.1M
5.3% of shares · 10.3 days to cover
Day range
$14.63$14.97
Open $14.69 Close $14.70
52-week closing range
$13.95$18.62
Close $14.70 21.1% under the high
Short volume, last session
31%
Last earnings
Feb 26, 2026
Latest filing
10-Q · Oct 30
Price history
Jan 2020 to Nov 2026

Latest documents

2026
Oct 30
Quarterly report 10-Q FY2026 Q3, ended Sep 30
LUPKYNIS sales rise 18% as cash reaches $486.9 million

Aurinia Pharmaceuticals reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, while cash, cash equivalents, restricted cash and investments totaled $486.9 million as of September 30, 2026.

Revenue $83.7M ▲ 13.9% Net income $31.7M ▲ 0.5% Diluted EPS $0.23 ▲ unchanged
Read from the MD&A section
2 source passages
For the three and nine months ended September 30, 2026, net product sales of LUPKYNIS were $79.4 million and $232.4 million, up 12% and 18%, respectively, from $70.6 million and $197.2 million, respectively, for the same periods in 2025. As of September 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $486.9 million, compared to $398.0 million at December 31, 2025. Open the document at this passage
Oct 30
Current report 8-K
Quarterly Revenue Rises 14% to $83.7 Million; 2026 Revenue Guidance Raised

Aurinia reported total revenue of $83.7 million for the three months ended September 30, 2026, up 14% from the prior-year period, and raised its 2026 total revenue guidance to $325 million to $330 million. Net income was $31.7 million for the quarter, flat year over year.

Financial results
3 source passages
For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million. For the three and nine months ended September 30, 2026, net income was $31.7 million and $103.5 million, flat and up 35%, respectively, from $31.6 million and $76.4 million, respectively, in the same periods of 2025. Open the document at this passage
Aug 19
Current report 8-K
Other events AI summary on its way
Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $83.22M ▲ 18.9% Net income $37.41M ▲ 73.9% Diluted EPS $0.28 ▲ 75.0%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$321.74M
Trailing 12 months
Net income (TTM)
$314.27M
Trailing 12 months
Revenue growth YoY
+13.9%
Year over year
Operating margin
48.6%
Trailing 12 months
P / E (TTM)
6.4
Trailing earnings · reciprocal yield 15.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$9.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.6%
Year over year · fewer shares
Price change (1Y)
-2.9%
Trailing year
Short interest
5.3%
Latest settlement · 10.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −7%
below
Price vs 50-day avg −10%
below
RSI (14) 30
neutral
MACD trend Negative
52-week position 16%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −13%
trailing
6-month return −4%
trailing
YTD return −8%
this year
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +37 funds added
Insider flow Distributing
Net -$379.9K over 90 days · 100% sells
Short interest Falling
5.33% of shares out · ▼ -8.3% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
277 holders — mid 3-yr range
Squeeze score 58
elevated · 0–100
Fundamentals
Excellent
Revenue growth +20%
Y/Y
EPS growth +5075%
Y/Y
Valuation P/E 6.4
below peers
Buyback $150.0M
authorized
Quant / Vol
risk profile
Moderate
Volatility 36%
annualized · 1-yr
Max drawdown −22%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the 8-K filed Oct 30, 2026
Total revenue · 2026 Raised $325M – $330M
May 7, 2026 $315M – $325M changed to Oct 30, 2026 $325M – $330M
prior FY $283.06M midpoint +15.7% Y/Y
Net product sales · 2026 Raised $310M – $315M
May 7, 2026 $305M – $315M changed to Oct 30, 2026 $310M – $315M
Guided vs delivered · last 2 settled
Total revenue 2025
guided $275M – $280M
$283.06M Beat +2.0%
Net sales 2021
guided $40M – $50M
$45.61M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−7% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
30 Neutral
MACD trend
Negative Bearish
52-week position
16% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +37 funds added
Insider flow Distributing
Net -$379.9K over 90 days · 100% sells
Short interest Falling
5.33% of shares out · ▼ -8.3% MoM · 10.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
277 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $14 Now $15 · 16% Range high $19
vs 200-day avg -7% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Planned enrollment 150 2026 —
repurchase of common shares 5M nine months ended September 30, 2026 —
sites 50 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AUPH
Aurinia Pharmaceuticals Inc.
this stock
$1.97B -7.8% +20.4% 6.4 5.3%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
277
% held
59.2%
Net QoQ
+358.1K sh
Top holder
TANG CAPITAL MANAGEMENT L…
Held Float
View
Held by Funds
Fund positions
187
View
Short & Settlement
Short Interest Falling
Shares short
7.1M
Days to cover
10.3d
Change
-642.7K sh
View
Short Volume
Short vol %
31%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
2.6K
Value
$44.1K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
37.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$379.9K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$283.1M
Net income (FY)
$287.2M
EPS diluted
$2.07
View
Buybacks
Authorized
$150.0M
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 30, 2026
This year
16

Aurinia Pharmaceuticals reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, while cash, cash equivalents, restricted cash and investments totaled $486.9 million as of September 30, 2026.

View
Proposed Sales
Value
$158.5K
Shares
9.6K
Filed
Jun 5, 2026
View
Earnings & Events
Webcasts
Last webcast
Feb 26, 2026
View
Investor Relations
Latest news
Aurinia Pharmaceuticals Reports F…
Published
Oct 30, 2026
View

Performance

5D 20D 120D MTD YTD
AUPH -6.6% -12.8% -4.5% -11.7% -7.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +2.0% -3.6% +4.7% -3.0% -9.0%

Capital returns

Buyback program · as of Feb 29, 2024
Authorized
$150.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1600620 CUSIP 05156V102 13F (30d) 285 filings 254 filers Visit website Investor relations